|Epidermal growth factor receptor genotype in plasma DNA and outcome of chemotherapy in the Chinese patients with advanced non-small cell lung cancer|
|Zhuo Ming-lei1; Wu Mei-na1; Zhao Jun1; Song, Sonya Wei2; Bai Hua1; Wang Shu-hang1; Yang Lu1; An Tong-tong1; Wang Xin1; Duan Jian-chun1; Wang Yu-yan1; Guo Qing-zhi1; Liu Xu-yi1; Liu Ning-hong1; Wang Jie1|
|关键词||Non-small Cell Lung Cancer Plasma Epidermal Growth Factor Receptor Mutation First Line Chemotherapy Prognosis Targeted Therapy Gefitinib|
|刊名||CHINESE MEDICAL JOURNAL|
|WOS标题词||Science & Technology|
|类目[WOS]||Medicine, General & Internal|
|研究领域[WOS]||General & Internal Medicine|
|关键词[WOS]||PHASE-III TRIAL ; MUTATIONS ; GEFITINIB ; ADENOCARCINOMA ; CARBOPLATIN ; PACLITAXEL|
Background The genotype of epidermal growth factor receptor (EGFR) is associated with tyrosine kinase inhibitor and effectiveness of therapy, but its role in cytotoxic chemotherapy is still unknown. Previous studies indicated that certain EGFR mutations were associated with response and progression free survival following platinum based chemotherapy. Our recent studies have identified that EGFR genotypes in the tumour tissues were not associated with response to the first-line chemotherapy in Chinese patients with advanced non-small cell lung cancer (NSCLC). In this study, we investigated associations of EGFR genotypes from plasma of patients with advanced NSCLC and response to first-line chemotherapy and prognosis.
Methods We enrolled 145 advanced NSCLC patients who had received first-line chemotherapy in our department. We examined plasma EGFR genotypes for these patients and associations of EGFR mutations with response to chemotherapy and clinical outcomes.
Results There were 54 patients with known EGFR mutations and 91 cases of wild types. No significant difference was detected in the response rate to first-line chemotherapy between mutation carriers and wild-type patients (37.0% vs. 31.9%). The median survival time and 1-, 2-year survival rates were higher in mutation carriers than wild-types (24 months vs. 18 months, 85.7% vs. 65.7% and 43.7% vs. 25.9%, P=0.047). Clinical stage (IV vs. IIIb), response to the first-line chemotherapy (partial vs. no) and EGFR genotype were independent prognostic factors.
Conclusion Plasma EGFR mutations in the Chinese patients with advanced NSCLC is not a predictor for the response to first-line chemotherapy, but an independent prognostic factor indicating longer survival. Chin Med J2011;124(21):3510-3514
|项目编号||2006AA02A401 ; 30772472 ; 2-013-39|
|资助机构||National High Technology Research and Development Program of China ("863" Program) ; Capital Development Foundation ; Peking University|
|作者单位||1.Peking Univ, Sch Oncol, Dept Thorac Med Oncol,Minist Educ, Beijing Canc Hosp & Inst,Key Lab Carcinogenesis &, Beijing 100142, Peoples R China|
2.Capital Med Univ, Beijing Shijitan Hosp, Lab Oncol, Beijing 100038, Peoples R China
|Zhuo Ming-lei,Wu Mei-na,Zhao Jun,et al. Epidermal growth factor receptor genotype in plasma DNA and outcome of chemotherapy in the Chinese patients with advanced non-small cell lung cancer[J]. CHINESE MEDICAL JOURNAL,2011,124(21):3510-3514.|
|APA||Zhuo Ming-lei.,Wu Mei-na.,Zhao Jun.,Song, Sonya Wei.,Bai Hua.,...&Wang Jie.(2011).Epidermal growth factor receptor genotype in plasma DNA and outcome of chemotherapy in the Chinese patients with advanced non-small cell lung cancer.CHINESE MEDICAL JOURNAL,124(21),3510-3514.|
|MLA||Zhuo Ming-lei,et al."Epidermal growth factor receptor genotype in plasma DNA and outcome of chemotherapy in the Chinese patients with advanced non-small cell lung cancer".CHINESE MEDICAL JOURNAL 124.21(2011):3510-3514.|